...
首页> 外文期刊>American Journal of Sports Medicine >Second-look arthroscopic evaluation of cartilage lesions after mesenchymal stem cell implantation in osteoarthritic knees
【24h】

Second-look arthroscopic evaluation of cartilage lesions after mesenchymal stem cell implantation in osteoarthritic knees

机译:骨关节炎膝关节中间充质干细胞植入后软骨病变的二阶段关节镜分析

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background: Cartilage regenerative procedures have been receiving increased interest because of their potential to alter the progression of osteoarthritis (OA). The application of mesenchymal stem cells (MSCs) has been proposed as a new treatment option for OA based on the ability of these cells to differentiate into chondrocytes. Purpose: To investigate the clinical and second-look arthroscopic outcomes of MSC implantation and to identify prognostic factors associated with this treatment. Study Design: Case series; Level of evidence, 4. Methods: This study retrospectively evaluated 37 knees examined using second-look arthroscopic surgery after MSC implantation for cartilage lesions in OA knees. Clinical outcomes were evaluated according to the International Knee Documentation Committee (IKDC) score and Tegner activity scale, and cartilage repair was assessed using International Cartilage Repair Society (ICRS) grading. Statistical analyses were performed to identify various prognostic factors associated with the clinical and second-look arthroscopic outcomes. Results: The mean patient age was 57.4 years (range, 48-69 years), the mean follow-up period was 26.5 months (range, 24-34 months), the mean body mass index (BMI) was 26.3 kg/m2 (range, 19.8-31.2 kg/m2), and the mean lesion size was 5.4 ± 2.9 cm2 (range, 2.3-8.9 cm2). The mean IKDC and Tegner activity scale scores were significantly improved from 38.0 ± 7.8 to 61.0 ± 11.0 and from 2.5 ± 0.5 to 3.6 ± 0.7, respectively (P .001 for both). According to the ICRS overall repair grades at second-look arthroscopic surgery, 2 of the 37 lesions (5%) were grade I (normal), 7 (19%) were grade II (near normal), 20 (54%) were grade III (abnormal), and 8 (22%) were grade IV (severely abnormal). In terms of overall patient satisfaction with the operation, 33 (94%) patients reported good to excellent satisfaction. High BMI (≥27.5 kg/m2) and large lesion size (≥5.4 cm2) were found to be significant predictors of poor clinical and arthroscopic outcomes (P .05 for both). Other prognostic factors, including patient age, sex, cartilage lesion location, and presence of subchondral cysts, did not significantly influence the outcomes (P .05). Conclusion: The outcomes of MSC implantation for cartilage repair in OA knees seem encouraging; high BMI and large lesion size are important factors affecting outcomes. Although still in the early stages of application, MSC implantation for cartilage repair may have great potential for the treatment of OA knees. However, second-look arthroscopic findings revealed that 76% had the repair rated as abnormal or severely abnormal by ICRS standards. The development of an advanced surgical procedure with tissue-engineered scaffolds may be needed to treat patients with large cartilage lesions.
机译:背景:由于其可能改变骨关节炎进展(OA)的可能性,软骨再生程序已接受增加的兴趣。基于这些细胞分化为软骨细胞的能力,已经提出了间充质干细胞(MSCs)作为OA的新治疗选择。目的:探讨MSC植入的临床和二看关节镜检查,并鉴定与该处理相关的预后因素。研究设计:案例系列;证据水平,4.方法:本研究回顾性地评估了在OA膝关节中的软骨病变的MSC植入后使用二看关节镜手术检查37个膝关节。根据国际膝关节文件(IKDC)得分和TEGNER活动规模,评估临床结果,并使用国际软骨修复社会(ICRS)评分评估软骨修复。进行统计分析以确定与临床和二看关节镜结果相关的各种预后因素。结果:平均患者年龄为57.4岁(范围,48-69岁),平均随访期为26.5个月(范围,24-34个月),平均体重指数(BMI)为26.3千克/平均值(范围为19.8-31.2 kg / m2),平均病变尺寸为5.4±2.9 cm2(范围,2.3-8.9 cm2)。平均IKDC和TEGNER活动量表评分分别从38.0±7.8到61.0±11.0分别显着提高到61.0±11.0±11.0±0.5至3.6±0.7(两个用于两者的P <.001)。根据ICRS在二看关节镜手术中的整体修复等级,37个病变(5%)中的2级是I(正常),7(19%)是II级(近正常),20(54%)为等级III(异常)和8(22%)是IV级(严重异常)。就整体患者满意于手术而言,33例(94%)患者报告了良好的满意度。发现高BMI(≥27.5kg/ m2)和大的病变大小(≥5.4cm2)是临床和关节镜结果不良的重要预测因子(两者都有p <.05)。其他预后因素,包括患者年龄,性别,软骨病变位置和潜水性囊肿的存在,并没有显着影响结果(P& .05)。结论:MSC植入植入软骨修复的结果似乎鼓励;高BMI和大型病变大小是影响结果的重要因素。虽然仍处于应用的早期阶段,但MSC植入软骨修复可能具有很大的潜力对OA膝盖的潜力。然而,第二外关关节镜发现显示,76%的维修被ICRS标准被视为异常或严重异常。可能需要开发具有组织工程支架的高级外科手术来治疗大软骨病变的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号